Tag: NASDAQ: DARE

Business

Dare Bioscience Inc (NASDAQ: DARE) Announces Collaborative Research Agreement for the Vital Stage 3 Study of Ovaprene®

Dare Bioscience Inc (NASDAQ: DARE) arrived into a Cooperative Research and Development Agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development for the essential Stage 3 study of Ovaprene®. Ovaprene® is a trial hormone-free regular intravaginal contraceptive presently in scientific development for the deterrence of the prenatal […]

Business

Dare Bioscience Inc (NASDAQ: DARE) Stock Trades At $1.83: The Stock Zooms To $2.26 On The News Of $49 Million Grant By Bill & Gates Foundation

Dare Bioscience Inc (NASDAQ: DARE) stock now trades at $1.83 (down 2.76%). It jumped to $2.26 after Bill & Gates foundation decided to grant up to $49 million.  Dare Bioscience will use the grant for technology development and preclinical activities for advancing its Dare-Larc1, an investigational contraceptive, into human clinical […]

Business

Dare Bioscience Inc (NASDAQ: DARE) Announces Encouraging Phase 1 Consequences for DARE-HRT1

Dare Bioscience Inc (NASDAQ: DARE) announced encouraging topline consequences from its Phase 1 scientific pilot of DARE-HRT1. DARE-HRT1 is a novel IVR intended to transport bio-identical 17β-estradiol and bio-identical progesterone unceasingly over 28 days. Consequences Support Latent as the First Cyclic Treatment for both the Vasomotor and the Vaginal Indications […]